

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Dec 10, 2021

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/novartis-data-highlight-efficacy-piqray-hrher2-metastatic-breast-cancer-pik3ca-driver-mutation-immediately-post-cdk46i-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-data-highlight-efficacy-piqray-hrher2-metastatic-breast-cancer-pik3ca-driver-mutation-immediately-post-cdk46i-0>